Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Ionis Pharmaceuticals's pretax income for the
three
months ended in Jun. 2026 was MXN-1,978 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-10,102 Mil.
Ionis Pharmaceuticals's pretax margin was -42.31%.
During the past 13 years, Ionis Pharmaceuticals's highest Pretax Margin was 30.18%. The lowest was -65.25%. And the median was -16.94%.
During the past 13 years, Ionis Pharmaceuticals's highest Pretax Margin was 30.18%. The lowest was -65.25%. And the median was -16.94%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals Pre-Tax Income Related Terms
Ionis Pharmaceuticals Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:IONS vs APGE, CYTK, KRYS: Pre-Tax Income Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-10,102 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Pre-Tax Income of MXN-10,102 Mil mean?
Ionis Pharmaceuticals (MEX:IONS) has a Pre-Tax Income of MXN-10,102 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Pre-Tax Income too high?
Ionis Pharmaceuticals' current Pre-Tax Income is MXN-10,102 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Pre-Tax Income compare to APGE and CYTK?
Ionis Pharmaceuticals' Pre-Tax Income of MXN-10,102 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Pre-Tax Income is MXN-10,102 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (MEX:IONS) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN683.35, compared to a current price of MXN960.00 — trading 40.5% above its estimated fair value. The current Pre-Tax Income is MXN-10,102 Mil. Ionis Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Pre-Tax Income is MXN-10,102 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN960.00 is trading 40.5% above its estimated GF Value™ of MXN683.35.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEX:IONS:
Pre-Tax Income: MXN-10,102 Mil
GF Value™: MXN683.35 vs. price of MXN960.00 (40.5% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
63GF Score
Get the complete analysis for MEX:IONS
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
